Zealand Pharma to Host a Capital Markets Day in New York

-- Thursday, 29 November 2012 from 07:30 - 11:00 EST
-- The event will also be available from the company's website via a live audio webcast with access to online presentations

COPENHAGEN, Denmark, Nov. 27, 2012 (GLOBE NEWSWIRE) -- Investor News
No. 9/2012

Zealand Pharma A/S (NASDAQ OMX: ZEAL), a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, will host a Capital Markets Day for analysts and investors in New York, USA on Thursday, 29 November 2012 from 07:30 – 11:00 EDT.

The event will feature a presentation from Dr. Leonid Poretsky, MD, Chief, Division of Endocrinology and Metabolism, Director, Gerald J. Friedman Diabetes Institute who will speak on diabetes classification, management and treatment goals, as well as controversies and news surrounding the disease and its treatment.

Other guest speakers include Alex Monteith, Executive Director of Business Development of the US Division of Helsinn Healthcare, one of Zealand Pharma's partners, and Dr. Barbara Ruskin, an IP and patent specialist, BA Ruskin Law, LCC.

Presentations will also be given by Zealand Pharma's management team, providing an update on the company's product pipeline with particular focus on its lead invention Lyxumia® (lixisenatide), a once-daily GLP-1 agonist licensed to and developed by Sanofi for the treatment of Type 2 diabetes. On 16 November, the Committee for Medicinal Products for Human Use under the European Medicines Agency issued a positive recommendation for the approval of Lyxumia® in the EU. Management will also give an update on the status of the company's partnership with Boehringer Ingelheim in diabetes/obesity and insight into the company's preclinical peptide drug activities in the diabetes/metabolic field.

No new material information will be disclosed at the event.

The event can be followed via a live audio webcast including access to online slide presentations. Participants are advised to register for the webcast approximately 10 minutes before the start. A replay of the event will be available shortly after the event and valid until 29 November 2013.

Event details
DATE: Thursday, 29 November 2012
TIME: 07:30 – 11:00 EST (webcast will start at 8:15am EST)
WEBCAST & REPLAY http://www.investorcalendar.com/IC/CEPage.asp?ID=170278

VENUE Le Parker Meridien, 119 West 56th Street, NYC

For further information, please contact:
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication
Tel: +45 5060 3689, email: hlh@zealandpharma.com

About Zealand Pharma
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company's focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide (Lyxumia® 1), a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. In November 2012, lixisenatide was given a CHMP positive opinion in Europe and a regulatory filing in the United States is expected in December 2012.

Zealand Pharma has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Abbott in acute kidney injury and Helsinn Healthcare in chemotherapy induced diarrhea. Zealand Pharma focuses its activities in disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. For further information: www.zealandpharma.com

1. Lyxumia is the proprietary name submitted to the EMA for lixisenatide. The proprietary name for lixisenatide in the United States is under consideration. Lixisenatide is not currently approved or licensed anywhere in the world.

Source:Zealand Pharma A/S